Adagrasib Vs. Sotorasib: Fda-Approved Kras G12C Inhibitors For Lung Cancer
Adagrasib and sotorasib are FDA-approved KRAS G12C inhibitors for non-small cell lung cancer. Adagrasib showed higher ORR, confirmed ORR, and PFS compared to sotorasib. Both drugs have similar safety profiles, with diarrhea, nausea, and fatigue being common adverse events. However, adagrasib is dosed once daily, while sotorasib is dosed twice daily, potentially impacting patient adherence….